The FDA approves low-dose colchicine for widespread CV indications.

Published Date: 24 Jun 2023

For patients with established atherosclerotic disease or multiple risk factors, the medication is the first specific anti-inflammatory drug for the reduction of cardiovascular events.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

2.

New drug combination shows good results in patients with HPV-negative head and neck cancer

3.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.

4.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

5.

Formaldehyde Causes More Cancer Than Any Other Toxic Air Pollutant


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot